The ISPE Biotechnology Conference in Dublin from 26-27 June, will provide an overview of the development and manufacturing of biotechnology products. This event will give originator pharmaceuticals, such as mABs and vaccines, the opportunity to increase productivity, process intensification, flexibility, and agility when it comes to mass production.

The conference will focus on different challenges for innovative, biosimilar, and follow-up biotechnology products, such as cell and gene therapy, Advanced Therapeutic Medicinal Products (ATMPs), and mRNA-based products - like vaccines. Presentations will be given on topics such as time to market, shortened submission approval times, product transfer, new concepts for control strategy, quality oversight, manufacturing, and logistics.

The ISPE Biotechnology Conference will explore the overarching themes that represent learnings from the originator pharmaceutical products that can be applied and transferred to the (new) biosimilar and follow-up biotechnology products. Methodological enablers for process development, supply chain resiliency, and sustainability - driven by the energy crisis - will be the primary focus of the event. Discussions will be presented and considered within the current regulatory framework.